25 LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

25 LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$429	–	108
2023 Q2	$429	Hold	5	–	–	﹤0.01%	592
2023 Q1	$480	Buy	+5	New	+$518	﹤0.01%	423

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

25 LLC's BMRN Position: Q3 2023 in Review

25 LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 5 shares — an estimated $429 sold.

25 LLC first reported a position in BMRN in Q1 2023 and held it in 2 quarters. The position peaked at $480 in Q1 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

25 LLC reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
25 LLC sold 5 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $429.
25 LLC first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 2 quarters.
25 LLC's BioMarin Pharmaceuticals position peaked at $480 in Q1 2023.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.